Eli Lilly Announces Major Acquisition of Kelonia Therapeutics
Eli Lilly announced on Monday that it is acquiring Kelonia Therapeutics, a developer of gene therapies focused on cancer treatment, in a deal valued at up to $7 billion in cash. This acquisition represents the largest purchase of a venture-backed biotech company in years, according to Crunchbase News.
Details of the Deal and Kelonia’s Background
The agreement includes an upfront payment of $3.25 billion, plus up to $3.75 billion in additional payments tied to clinical, regulatory, and commercial milestones. Kelonia, based in Boston, launched from stealth mode four years ago with $50 million in Series A funding led by Alta Partners, Horizons Ventures, and Venrock. Two years after its launch, Kelonia entered a research and licensing partnership with Xyphos Biosciences, a subsidiary of Japan’s Astellas Pharma, to develop immuno-oncology therapeutics using its in vivo gene placement system.
Kelonia’s platform aims to improve patient outcomes through a simpler “off-the-shelf” format compared to existing CAR T-cell therapies, by reprogramming patients’ T-cells inside the body to target cancer. As is widely known, the biotech industry often involves rapid advancements in gene therapies, and this deal highlights Kelonia’s quick progression from startup to acquisition.
Rising Trend in In Vivo Therapeutics Acquisitions
Recent acquisitions show a pattern of high valuations for startups in in vivo therapeutics. For instance, Lilly purchased Orna Therapeutics, another company focused on engineering immune cells in vivo, in a deal valued at up to $2.4 billion just two months ago, according to Crunchbase News. Other examples include AbbVie’s acquisition of Capstan Therapeutics for $2.1 billion last June and Bristol-Myers Squibb’s purchase of Orbital Therapeutics for $1.5 billion in October, both targeting RNA-based in vivo technologies.
Per Crunchbase data, Kelonia’s deal dwarfs these predecessors, ranking as the largest acquisition of a venture-backed, private biotech company in the past 10 years. Orna had raised over $320 million in venture funding, while Capstan secured $340 million, underscoring the scale of investment in this space.
Implications for Venture-Backed Biotechs
The acquisition terms for Kelonia emphasize milestone-based payments, which are common in biotech deals to align with development progress. According to Crunchbase News, this transaction builds on a list of the largest venture-funded private biotech startup acquisitions over the past decade. As a widely recognized trend, such deals can signal strong investor interest in innovative therapies, potentially influencing capital raising strategies for emerging fund managers in the sector.
